Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.

Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T.

Jpn J Clin Oncol. 2013 Apr;43(4):422-5. doi: 10.1093/jjco/hyt012. Epub 2013 Feb 13.

2.

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.

Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12. Review.

PMID:
22579408
3.

[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].

Katono K, Kasajima M, Ishihara M, Hayashi N, Nagashima Y, Igawa S, Masuda N.

Gan To Kagaku Ryoho. 2013 Mar;40(3):375-7. Japanese.

PMID:
23507602
4.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y, Ma S.

World J Surg Oncol. 2012 Nov 7;10:235. doi: 10.1186/1477-7819-10-235.

5.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

6.

Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.

Koma Y, Matsuoka H, Yoshimatsu H, Suzuki Y.

Int J Clin Pharmacol Ther. 2012 Oct;50(10):760-4. doi: 10.5414/CP201759. Review.

PMID:
22853866
7.

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.

J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.

PMID:
23804027
8.

[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].

Fujikura Y, Morishima Y, Ota K, Otsuka S, Homma S, Kurishima K, Hizawa N.

Nihon Kokyuki Gakkai Zasshi. 2010 May;48(5):391-6. Japanese.

PMID:
20560443
9.

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1465-9. doi: 10.1007/s00280-011-1555-6. Epub 2011 Jan 28.

PMID:
21274533
10.

Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

Tammaro KA, Baldwin PD, Lundberg AS.

J Oncol Pharm Pract. 2005 Sep;11(3):127-30.

PMID:
16390601
11.

Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.

Yang H, Yang X, Zhang Y, Liu X, Deng Q, Zhao M, Xu X, He J.

Target Oncol. 2015 Mar;10(1):135-40. doi: 10.1007/s11523-014-0326-9. Epub 2014 Jul 2.

PMID:
24985049
12.

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T.

J Thorac Oncol. 2009 Nov;4(11):1415-9. doi: 10.1097/JTO.0b013e3181b62572.

PMID:
19692934
13.

[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].

Kitade H, Yamada T, Igarashi S, Hokkoku K, Mori M, Shintaku K, Sagawa M, Nakai M, Yano S.

Gan To Kagaku Ryoho. 2013 Jan;40(1):79-81. Japanese.

PMID:
23306923
14.

[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].

Mitsuya K, Nakasu Y, Mizokami Y, Takahashi T, Nakamura Y, Ono A, Toda Y, Yamamoto N, Harada H, Nishimura T.

No Shinkei Geka. 2012 Jun;40(6):503-9. Japanese.

PMID:
22647509
15.

Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.

Kuo LC, Lin PC, Wang KF, Yuan MK, Chang SC.

Med Oncol. 2011 Mar;28(1):79-82. doi: 10.1007/s12032-010-9424-4. Epub 2010 Jan 20. Review.

PMID:
20087691
16.

Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.

Lai YC, Lin PC, Lai JI, Hsu SY, Kuo LC, Chang SC, Wang WS.

Int J Clin Pharmacol Ther. 2011 Jul;49(7):461-6.

PMID:
21726497
17.

Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.

Wang KF, Chang CY, Chang SC, Liu YC, Yuan MK, Yang YH.

J Chin Med Assoc. 2013 Mar;76(3):173-5. doi: 10.1016/j.jcma.2013.01.012. Epub 2013 Feb 27.

18.

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.

Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, Mitsufuji H, Kubota M, Katagiri M, Masuda N.

Cancer Chemother Pharmacol. 2010 Mar;65(4):803-6. doi: 10.1007/s00280-009-1212-5. Epub 2009 Dec 25.

PMID:
20035424
19.

Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.

Takenaka T, Yamagata M, Fukuda A, Sonoda T.

BMJ Case Rep. 2011 Sep 13;2011. pii: bcr0820114586. doi: 10.1136/bcr.08.2011.4586.

20.

[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].

Ohashi Y, Suzuki K, Sakurai M, Shino M, Murakami H, Takahashi T, Yamamoto N.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1327-31. Japanese.

PMID:
19692772
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk